Article
Lack of effect of Imrecoxib, an innovative and moderate COX-2 inhibitor, on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
Scientific reports - 31 Oct 2019
Liu Yani, Zhang Rui, Li Zhongfang, Zhou Jiali, Yang Tingyu, Yang Chunxiao, Huang Xixi, Zhang Yu, Shi Shaojun
Abstract excerpt
Imrecoxib is a registered treatment for osteoarthritis pain symptoms in China. This study aims to assess the effect of imrecoxib on the pharmacodynamics and pharmacokinetics of warfarin. 12 healthy male volunteers with CYP2C9*3 AA and VKORC1 AA genotypes took a 5 mg dose of warfarin both alone and concomitantly with steady-state imrecoxib. Both warfarin alone and concomitantly with imrecoxib have safey and good...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.